These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29924867)

  • 21. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
    Qu G; Liu C; Sun B; Zhou C; Zhang Z; Wang P
    Oncol Rep; 2014 Jul; 32(1):341-7. PubMed ID: 24842595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tivantinib (ARQ-197) exhibits anti-tumor activity with down-regulation of FAK in oral squamous cell carcinoma.
    Xi WH; Yang LY; Cao ZY; Qian Y
    Biochem Biophys Res Commun; 2015 Feb; 457(4):723-9. PubMed ID: 25623532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone Pain Induced by Multiple Myeloma Is Reduced by Targeting V-ATPase and ASIC3.
    Hiasa M; Okui T; Allette YM; Ripsch MS; Sun-Wada GH; Wakabayashi H; Roodman GD; White FA; Yoneda T
    Cancer Res; 2017 Mar; 77(6):1283-1295. PubMed ID: 28254863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance.
    Aoyama A; Katayama R; Oh-Hara T; Sato S; Okuno Y; Fujita N
    Mol Cancer Ther; 2014 Dec; 13(12):2978-90. PubMed ID: 25313010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
    Slørdahl TS; Denayer T; Moen SH; Standal T; Børset M; Ververken C; Rø TB
    Eur J Haematol; 2013 Nov; 91(5):399-410. PubMed ID: 23952536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
    Buckle CH; De Leenheer E; Lawson MA; Yong K; Rabin N; Perry M; Vanderkerken K; Croucher PI
    PLoS One; 2012; 7(8):e41127. PubMed ID: 22952578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease.
    Pennisi A; Li X; Ling W; Khan S; Gaddy D; Suva LJ; Barlogie B; Shaughnessy JD; Aziz N; Yaccoby S
    Br J Haematol; 2009 Jun; 145(6):775-87. PubMed ID: 19388929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.
    Fujita H; Gomori A; Fujioka Y; Kataoka Y; Tanaka K; Hashimoto A; Suzuki T; Ito K; Haruma T; Yamamoto-Yokoi H; Harada N; Sakuragi M; Oda N; Matsuo K; Inada M; Yonekura K
    PLoS One; 2016; 11(10):e0164830. PubMed ID: 27736957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.
    Adjei AA; Schwartz B; Garmey E
    Oncologist; 2011; 16(6):788-99. PubMed ID: 21632449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TGFβ Inhibition Stimulates Collagen Maturation to Enhance Bone Repair and Fracture Resistance in a Murine Myeloma Model.
    Green AC; Lath D; Hudson K; Walkley B; Down JM; Owen R; Evans HR; Paton-Hough J; Reilly GC; Lawson MA; Chantry AD
    J Bone Miner Res; 2019 Dec; 34(12):2311-2326. PubMed ID: 31442332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease.
    Gooding S; Olechnowicz SWZ; Morris EV; Armitage AE; Arezes J; Frost J; Repapi E; Edwards JR; Ashley N; Waugh C; Gray N; Martinez-Hackert E; Lim PJ; Pasricha SR; Knowles H; Mead AJ; Ramasamy K; Drakesmith H; Edwards CM
    Nat Commun; 2019 Oct; 10(1):4533. PubMed ID: 31586071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts.
    Faict S; Muller J; De Veirman K; De Bruyne E; Maes K; Vrancken L; Heusschen R; De Raeve H; Schots R; Vanderkerken K; Caers J; Menu E
    Blood Cancer J; 2018 Nov; 8(11):105. PubMed ID: 30409995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of an in vivo model of human multiple myeloma bone disease.
    Alsina M; Boyce B; Devlin RD; Anderson JL; Craig F; Mundy GR; Roodman GD
    Blood; 1996 Feb; 87(4):1495-501. PubMed ID: 8608240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.
    Basilico C; Pennacchietti S; Vigna E; Chiriaco C; Arena S; Bardelli A; Valdembri D; Serini G; Michieli P
    Clin Cancer Res; 2013 May; 19(9):2381-92. PubMed ID: 23532890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease.
    Eda H; Santo L; Wein MN; Hu DZ; Cirstea DD; Nemani N; Tai YT; Raines SE; Kuhstoss SA; Munshi NC; Kronenberg HM; Raje NS
    J Bone Miner Res; 2016 Jun; 31(6):1225-34. PubMed ID: 26763740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models.
    Paton-Hough J; Tazzyman S; Evans H; Lath D; Down JM; Green AC; Snowden JA; Chantry AD; Lawson MA
    J Bone Miner Res; 2019 May; 34(5):783-796. PubMed ID: 30320927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model.
    Schwarzer R; Nickel N; Godau J; Willie BM; Duda GN; Schwarzer R; Cirovic B; Leutz A; Manz R; Bogen B; Dörken B; Jundt F
    Blood Cancer J; 2014 Jun; 4(6):e217. PubMed ID: 24927406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted therapies: Tivantinib--a cytotoxic drug in MET inhibitor's clothes?
    Michieli P; Di Nicolantonio F
    Nat Rev Clin Oncol; 2013 Jul; 10(7):372-4. PubMed ID: 23712183
    [No Abstract]   [Full Text] [Related]  

  • 39. A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer.
    Kang YK; Muro K; Ryu MH; Yasui H; Nishina T; Ryoo BY; Kamiya Y; Akinaga S; Boku N
    Invest New Drugs; 2014 Apr; 32(2):355-61. PubMed ID: 24337769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.
    Xiang Q; Zhen Z; Deng DY; Wang J; Chen Y; Li J; Zhang Y; Wang F; Chen N; Chen H; Chen Y
    J Exp Clin Cancer Res; 2015 Oct; 34():118. PubMed ID: 26458953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.